ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China ACN Newswire
May 07, 2025Everest Medicines announced that the supplemental New Drug Application (sNDA) for NEFECON has received full approval from the China National Medical Products Administration (NMPA). -
Everest Medicines announces FDA grants our Partner Calliditas Therapeutics Accelerated Approval of TARPEYO? (budesonide) to Reduce Proteinuria in IgA Nephropathy prnasia
December 17, 2021Everest Medicines Limited (HKEX 1952.HK) today reported that Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") announced that the US Food and Drug Administration (FDA)... -
FDA approves first drug to decrease urine protein in IgA nephropathy, a rare kidney disease FDA
December 16, 2021FDA has granted accelerated approval for?Tarpeyo (budesonide) delayed release capsules to reduce proteinuria (increased protein levels in the urine) in adults with primary immunoglobulin A (IgA) nephropathy at risk of rapid disease progression. -
Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis firstwordpharma
May 26, 2021Travere Therapeutics, Inc. today provided a regulatory update for its sparsentan program in focal segmental glomerulosclerosis (FSGS).
Pharma Sources Insight January 2025
